Making the Most of Molecular Testing in Breast Cancer

Partner | Cancer Centers | <b>UCSD Moores Cancer Center </b>

Drs. Brown and Kurzrock discuss the current and future applications of next-generation sequencing in breast cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.

Welcome to OncLive On Air®! I’m your host today, Jessica Hergert.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by NeoGenomics, we had the pleasure of speaking with Razelle Kurzrock, MD, director of the Center for Personalized Cancer Therapy, director of the Rare Tumor Clinic, and the associate center director of Clinical Science at University of California, San Diego Moores Cancer Center, and Shari Brown, MD, director of molecular pathology services at NeoGenomics, to discuss the current role of next-generation sequencing in breast cancer.

In our exclusive interview, Brown and Kurzrock discussed the current and future applications of next-generation sequencing in breast cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.